Literature DB >> 22432083

Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.

Vaishali Sanchorawala1.   

Abstract

AL amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. The disease is often difficult to recognize because of its broad range of manifestations and, what are often, vague symptoms. Recent diagnostic and prognostic advances include the serum free light chain assay, cardiac magnetic resonance imaging, and serologic cardiac biomarkers. Treatment strategies that have evolved during the past decade are prolonging survival and preserving organ function in patients with this disease. This review outlines the role of high dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.

Entities:  

Keywords:  AL amyloidosis; melphalan; stem cell transplantation

Year:  2012        PMID： 22432083      PMCID： PMC3301435     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN： 2160-1992


  52 in total

1.  High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.

Authors:  V Sanchorawala; D G Wright; D C Seldin; R H Falk; K T Finn; L M Dember; J L Berk; K Quillen; J J Anderson; R L Comenzo; M Skinner
Journal:  Bone Marrow Transplant       Date:  2004-02       Impact factor: 5.483

2.  Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.

Authors:  Angela Dispenzieri; Robert A Kyle; Martha Q Lacy; Terry M Therneau; Dirk R Larson; Matthew F Plevak; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; Morie A Gertz
Journal:  Blood       Date:  2004-01-22       Impact factor: 22.113

3.  Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis.

Authors:  Stefan O Schonland; Jolanta B Perz; Michael Hundemer; Ute Hegenbart; Arnt V Kristen; Ernst Hund; Thomas J Dengler; Jorg Beimler; Martin Zeier; Reinhard Singer; Reinhold P Linke; Anthony D Ho; Hartmut Goldschmidt
Journal:  Transplantation       Date:  2005-09-27       Impact factor: 4.939

4.  Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

Authors:  Maria Teresa Cibeira; Vaishali Sanchorawala; David C Seldin; Karen Quillen; John L Berk; Laura M Dember; Adam Segal; Frederick Ruberg; Hans Meier-Ewert; Nancy T Andrea; J Mark Sloan; Kathleen T Finn; Gheorghe Doros; Joan Blade; Martha Skinner
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

5.  Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis.

Authors:  H K Meier-Ewert; V Sanchorawala; J Berk; K T Finn; M Skinner; D C Seldin; F L Ruberg
Journal:  Amyloid       Date:  2011-06       Impact factor: 7.141

6.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

7.  Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.

Authors:  B Oran; K Malek; V Sanchorawala; D G Wright; K Quillen; K T Finn; M La Valley; M Skinner; D C Seldin
Journal:  Bone Marrow Transplant       Date:  2005-03       Impact factor: 5.483

8.  Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

Authors:  Giovanni Palladini; Carlo Campana; Catherine Klersy; Alessandra Balduini; Giovanbattista Vadacca; Vittorio Perfetti; Stefano Perlini; Laura Obici; Edoardo Ascari; Gianvico Melzi d'Eril; Remigio Moratti; Giampaolo Merlini
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

9.  Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.

Authors:  L Q M Chow; N Bahlis; J Russell; A Chaudhry; D Morris; C Brown; D A Stewart
Journal:  Bone Marrow Transplant       Date:  2005-10       Impact factor: 5.483

10.  Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.

Authors:  Morie Gertz; Martha Lacy; Angela Dispenzieri; Suzanne Hayman; Shaji Kumar; Francis Buadi; Nelson Leung; Mark Litzow
Journal:  Leuk Lymphoma       Date:  2008-01
View more
  2 in total

1.  Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.

Authors:  V Sanchorawala; A Hoering; D C Seldin; K T Finn; S A Fennessey; R Sexton; B Mattar; H F Safah; L A Holmberg; R M Dean; R Z Orlowski; B Barlogie
Journal:  Bone Marrow Transplant       Date:  2013-07-15       Impact factor: 5.483

Review 2.  Heart transplantation in cardiac amyloidosis.

Authors:  Matthew Sousa; Gregory Monohan; Navin Rajagopalan; Alla Grigorian; Maya Guglin
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.